| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Basic Study |
| Article Title |
Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Min-Woo Chung, Moon-Ju Kim, Eun Jeong Won, Yu Jeong Lee, Yong-Woon Yun, Sung Bum Cho, Young-Eun Joo, Jun-Eul Hwang, Woo Kyun Bae, Ik-Joo Chung, Myung Geun Shin and Jong Hee Shin |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Research Foundation of Korea |
NRF-2019R1C1C1004605 |
| National Research Foundation of Korea |
NRF-2019M3E5D1A02067953 |
| National Research Foundation of Korea |
NRF-2021M3E5D1A0201518021 |
|
| Corresponding Author |
Eun Jeong Won, MD, PhD, Professor, Department of Parasitology and Tropical Medicine, Chonnam National University Medical School, 322, Seoyang-ro, Hwasun-eup, Hwasun 58128, Jeollanam-do, South Korea. parasite.woni@jnu.ac.kr |
| Key Words |
Microbiome; Nivolumab; Firmicutes/Bacteroidetes ratio; Prevotella/Bacteroides ratio; Hepatocellular carcinoma; Prognosis |
| Core Tip |
Immune check point inhibitors are known to be an effective treatment option for advanced hepatocellular carcinoma (HCC), not only for second-line, but also as a first-line treatment. However, there are few predictive or prognostic markers for which patient group will have a good treatment response to immunotherapy or systemic therapy for HCC until now. Our study shows that non-responders to nivolumab in HCC patients have dysbiotic fecal composition, whereas a high Prevotella/Bacteroides ratio can predict a better response to nivolumab, highlighting a potential role for the gut microbiome as a prognostic marker for the response to nivolumab therapy. |
| Publish Date |
2021-11-10 07:13 |
| Citation |
Chung MW, Kim MJ, Won EJ, Lee YJ, Yun YW, Cho SB, Joo YE, Hwang JE, Bae WK, Chung IJ, Shin MG, Shin JH. Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients. World J Gastroenterol 2021; 27(42): 7340-7349 |
| URL |
https://www.wjgnet.com/1007-9327/full/v27/i42/7340.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v27.i42.7340 |
